Solasia Pharma K.K Past Earnings Performance
Past criteria checks 0/6
Solasia Pharma K.K has been growing earnings at an average annual rate of 6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 9% per year.
Key information
6.0%
Earnings growth rate
15.2%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 9.0% |
Return on equity | -59.3% |
Net Margin | -180.2% |
Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Solasia Pharma K.K makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 617 | -1,112 | 1,073 | 403 |
30 Sep 23 | 1,209 | -1,267 | 1,522 | 425 |
30 Jun 23 | 1,432 | -1,738 | 1,801 | 728 |
31 Mar 23 | 1,199 | -2,174 | 2,025 | 799 |
31 Dec 22 | 1,092 | -2,548 | 2,250 | 883 |
30 Sep 22 | 761 | -2,416 | 2,119 | 789 |
30 Jun 22 | 470 | -2,331 | 2,091 | 575 |
31 Mar 22 | 581 | -2,437 | 2,019 | 764 |
31 Dec 21 | 559 | -2,478 | 1,948 | 845 |
30 Sep 21 | 450 | -4,301 | 2,714 | 1,747 |
30 Jun 21 | 492 | -4,249 | 2,573 | 1,826 |
31 Mar 21 | 389 | -4,252 | 2,475 | 1,931 |
31 Dec 20 | 454 | -4,127 | 2,432 | 1,928 |
30 Sep 20 | 1,306 | -2,132 | 1,840 | 1,425 |
30 Jun 20 | 1,420 | -2,046 | 1,926 | 1,402 |
31 Mar 20 | 1,405 | -1,838 | 1,948 | 1,150 |
31 Dec 19 | 1,310 | -1,867 | 1,868 | 1,138 |
30 Sep 19 | 499 | -2,561 | 1,491 | 1,286 |
30 Jun 19 | 364 | -2,599 | 1,275 | 1,435 |
31 Mar 19 | 372 | -2,662 | 1,198 | 1,555 |
31 Dec 18 | 318 | -2,422 | 1,061 | 1,463 |
30 Sep 18 | 111 | -2,129 | 888 | 1,275 |
30 Jun 18 | 489 | -1,378 | 827 | 971 |
31 Mar 18 | 414 | -1,086 | 701 | 798 |
31 Dec 17 | 410 | -1,007 | 647 | 773 |
30 Sep 17 | 709 | -493 | 628 | 512 |
31 Dec 16 | 501 | -762 | 488 | 475 |
31 Dec 15 | 229 | -917 | 458 | 473 |
31 Dec 14 | 11 | -677 | 476 | 237 |
Quality Earnings: 9SO is currently unprofitable.
Growing Profit Margin: 9SO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9SO is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare 9SO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9SO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 9SO has a negative Return on Equity (-59.31%), as it is currently unprofitable.